Tango Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Tango Therapeutics
TNGX Stock  USD 8.11  0.14  1.76%   
Tango Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tango Therapeutics' valuation are provided below:
Gross Profit
-112.2 M
Market Capitalization
1.1 B
Enterprise Value Revenue
29.2153
Revenue
24.3 M
Earnings Share
(1.32)
We have found one hundred twenty available fundamental trend indicators for Tango Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tango Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 406.3 M in 2025. Enterprise Value is likely to rise to about 372.1 M in 2025

Tango Therapeutics Total Revenue

31.68 Million

Check Tango Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tango Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 3.6 M or Selling General Administrative of 26.4 M, as well as many indicators such as Price To Sales Ratio of 7.62, Dividend Yield of 0.0 or PTB Ratio of 1.61. Tango financial statements analysis is a perfect complement when working with Tango Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Tango Stock
Check out the analysis of Tango Therapeutics Correlation against competitors.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Tango Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets351.8 M316.5 M173.3 M
Slightly volatile
Short and Long Term Debt Total24.5 M36.5 M14.3 M
Slightly volatile
Other Current Liabilities11.6 M16.5 M19.9 M
Slightly volatile
Total Current Liabilities45.3 M38.2 M32.8 M
Slightly volatile
Total Stockholder Equity200.4 M199.5 M85.3 M
Slightly volatile
Other Liabilities91.5 M131.9 M51.9 M
Slightly volatile
Property Plant And Equipment Net34.5 M47.6 M20.6 M
Slightly volatile
Accounts Payable2.7 M1.6 M1.5 M
Slightly volatile
Cash71.5 M69.5 M41.7 M
Slightly volatile
Non Current Assets Total37.2 M50.1 M22.9 M
Slightly volatile
Non Currrent Assets Other2 M2.6 M2.1 M
Pretty Stable
Other Assets1.5 M1.6 M12.4 M
Pretty Stable
Cash And Short Term Investments307.4 M257.9 M146.8 M
Slightly volatile
Common Stock Shares Outstanding72.4 M109.2 M34.2 M
Slightly volatile
Short Term Investments236 M188.4 M105.1 M
Slightly volatile
Liabilities And Stockholders Equity351.8 M316.5 M173.3 M
Slightly volatile
Non Current Liabilities Total106 M78.8 M55.1 M
Slightly volatile
Other Current Assets7 M8.4 M3.5 M
Slightly volatile
Other Stockholder Equity458.2 M700.6 M186.7 M
Slightly volatile
Total Liabilities151.3 M117 M88 M
Slightly volatile
Total Current Assets314.6 M266.3 M150.3 M
Slightly volatile
Short Term Debt2.3 M2.5 M1.3 M
Slightly volatile
Common Stock80.5 K108 K39.8 K
Slightly volatile
Property Plant Equipment8 M9.8 M11 M
Slightly volatile
Current Deferred Revenue21.3 M17.6 M29.6 M
Slightly volatile
Common Stock Total Equity75.2 K79.2 K108.2 M
Slightly volatile
Capital Lease Obligations27.7 M36.5 M14.5 M
Slightly volatile
Net Invested Capital238.8 M199.5 M106.9 M
Slightly volatile
Property Plant And Equipment Gross42.3 M55.9 M22.8 M
Slightly volatile
Capital Stock93.7 K108 K57.5 K
Slightly volatile
Non Current Liabilities Other90.3 M151.2 M38.7 M
Slightly volatile
Net Working Capital232.5 M228.2 M200.8 M
Slightly volatile
Capital Surpluse566.2 M601 M518.3 M
Slightly volatile
Inventory453.6 K510.3 K556.4 K
Slightly volatile

Tango Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M2.5 M1.1 M
Slightly volatile
Selling General Administrative26.4 M43.7 M14.9 M
Slightly volatile
Total Revenue31.7 M42.1 M26.6 M
Slightly volatile
Other Operating Expenses122.6 M187.7 M71.6 M
Slightly volatile
Research Development96.2 M143.9 M57 M
Slightly volatile
Cost Of Revenue2.4 M2.5 M28.2 M
Pretty Stable
Total Operating Expenses116.7 M187.7 M51.1 M
Slightly volatile
Total Other Income Expense Net16.3 M15.5 M3.7 M
Slightly volatile
Net Interest Income8.3 M7.9 M1.5 M
Slightly volatile
Interest Income8.3 M7.9 M1.5 M
Slightly volatile
Reconciled Depreciation1.8 M2.5 M1.1 M
Slightly volatile

Tango Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation30.3 M28.9 M7.4 M
Slightly volatile
Other Cashflows From Financing Activities5.6 M5.9 M13.9 M
Very volatile
Depreciation1.6 M2.5 M1 M
Slightly volatile
Capital Expenditures716.3 K754 K2 M
Very volatile
Total Cash From Financing Activities77.5 M47.7 M47.3 M
Slightly volatile
End Period Cash Flow74.6 M72.1 M44.2 M
Slightly volatile
Change To Netincome16.4 M15.6 M5.8 M
Slightly volatile
Begin Period Cash Flow73.6 M69.8 M41.2 M
Slightly volatile
Sale Purchase Of Stock24.8 M27.9 M30.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.628.022810.6398
Slightly volatile
PTB Ratio1.611.69168.5796
Slightly volatile
Days Sales Outstanding52.9533.7775.8754
Slightly volatile
Book Value Per Share2.01.82661.5563
Slightly volatile
Stock Based Compensation To Revenue0.720.68690.2269
Slightly volatile
Capex To Depreciation0.290.30172.3659
Slightly volatile
PB Ratio1.611.69168.5796
Slightly volatile
EV To Sales6.887.23759.664
Slightly volatile
Inventory Turnover4.236.394.1523
Slightly volatile
Days Of Inventory On Hand86.1559.0994.4502
Slightly volatile
Payables Turnover49.9547.5738.9364
Slightly volatile
Sales General And Administrative To Revenue0.71.03990.5463
Slightly volatile
Research And Ddevelopement To Revenue2.773.4212.2077
Slightly volatile
Capex To Revenue0.0170.01790.0823
Very volatile
Cash Per Share2.242.36134.4434
Pretty Stable
Days Payables Outstanding9.6410.1595.0214
Slightly volatile
Net Debt To EBITDA0.220.23090.8792
Slightly volatile
Current Ratio5.36.97783.7202
Slightly volatile
Tangible Book Value Per Share2.021.82661.5707
Slightly volatile
Receivables Turnover9.2711.196.6218
Slightly volatile
Shareholders Equity Per Share2.01.82661.5563
Slightly volatile
Debt To Equity0.310.18290.6871
Slightly volatile
Capex Per Share0.00660.00690.1377
Slightly volatile
Revenue Per Share0.370.38521.8557
Slightly volatile
Interest Debt Per Share0.430.33410.6681
Slightly volatile
Debt To Assets0.06510.11530.1141
Slightly volatile
Operating Cycle11092.8696.1608
Very volatile
Price Book Value Ratio1.611.69168.5796
Slightly volatile
Days Of Payables Outstanding9.6410.1595.0214
Slightly volatile
Ebt Per Ebit1.050.89350.9434
Slightly volatile
Company Equity Multiplier1.511.58635.2374
Slightly volatile
Total Debt To Capitalization0.20.15460.3623
Slightly volatile
Debt Equity Ratio0.310.18290.6871
Slightly volatile
Quick Ratio5.36.97783.7187
Slightly volatile
Net Income Per E B T0.81.00160.9866
Slightly volatile
Cash Ratio1.261.82161.1664
Slightly volatile
Days Of Inventory Outstanding86.1559.0994.4502
Slightly volatile
Days Of Sales Outstanding52.9533.7775.8754
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00571.0604
Slightly volatile
Price To Book Ratio1.611.69168.5796
Slightly volatile
Fixed Asset Turnover0.840.88421.9025
Pretty Stable
Debt Ratio0.06510.11530.1141
Slightly volatile
Price Sales Ratio7.628.022810.6398
Slightly volatile
Asset Turnover0.150.13290.3101
Slightly volatile
Price Fair Value1.611.69168.5796
Slightly volatile

Tango Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap406.3 M337.5 M267.5 M
Slightly volatile
Enterprise Value372.1 M304.5 M241 M
Slightly volatile

Tango Fundamental Market Drivers

Cash And Short Term Investments257.9 M

Tango Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tango Therapeutics Financial Statements

Tango Therapeutics investors use historical fundamental indicators, such as Tango Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tango Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue17.6 M21.3 M
Total Revenue42.1 M31.7 M
Cost Of Revenue2.5 M2.4 M
Stock Based Compensation To Revenue 0.69  0.72 
Sales General And Administrative To Revenue 1.04  0.70 
Research And Ddevelopement To Revenue 3.42  2.77 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.39  0.37 
Ebit Per Revenue(3.46)(3.63)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VOOVanguard SP 500
XLKTechnology Select Sector
XLVHealth Care Select

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY